Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
:HALO
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.96Last Year’s EPS
0.79Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 18, 2025
|% Change Since: -0.26%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call was largely positive, with record-breaking revenue, strong growth in key products, and an optimistic outlook for 2025 and beyond. While there were some setbacks, such as the delay in Amivantamab subcutaneous approval and temporary royalty rate impacts, these were overshadowed by the overall strong financial performance and strategic achievements.Company Guidance
During the call, Halozyme provided a detailed financial and operational update, highlighting record-breaking achievements in 2024 and offering guidance for 2025. The company reported total revenue exceeding $1 billion for the first time, marking a 22% growth over the previous year. Key financial metrics included royalty revenue growth of 27% to $571 million, a net income increase of 58% to $444 million, and an adjusted EBITDA of $632 million, up 48% year-over-year. For 2025, Halozyme projects total revenue between $1.15 billion and $1.225 billion, reflecting a 13% to 21% increase. Royalty revenues are expected to grow 27% to 31%, driven by products like DARZALEX subcutaneous, Phesgo, and VYVGART Hytrulo. The guidance also includes an adjusted EBITDA range of $755 million to $805 million, representing growth of 19% to 27%, and non-GAAP EPS between $4.95 and $5.35, indicating a 17% to 26% increase from 2024. The company remains confident in its long-term growth prospects, aiming for $1 billion in royalty revenue by 2027, supported by a robust pipeline and strategic partnerships.Record-Breaking Revenue
Total revenue exceeded $1 billion for the first time, growing 22% year-over-year, driven by strong royalty revenue and strategic management.
Strong Royalty Revenue Growth
Royalty revenue grew 27% year-over-year, reaching $571 million, exceeding the raised guidance.
DARZALEX Subcutaneous Growth
Johnson & Johnson reported worldwide sales of DARZALEX grew 24%, driven by the subcutaneous version which holds 95% share of total sales in the US.
Phesgo Adoption
Phesgo sales increased 72% year-over-year, with strong uptake across all regions, reaching CHF1.7 billion for full year 2024.
VYVGART Hytrulo Success
VYVGART Hytrulo with ENHANZE drove significant growth, with full year revenue reaching $2.2 billion, aided by its ease of use and adoption in CIDP.
New Approvals and Pipeline Expansion
Significant approvals in 2024 included Ocrevus Zunovo, Tecentriq Hybreza, and Opdivo Qvantiq, with contributions expected to become meaningful in 2026 and beyond.
Financial Strength and Guidance
Adjusted EBITDA increased 48% to $632 million, with a strong balance sheet and projections for continued growth in 2025.
---
HALO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HALO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 18, 2025 | $57.90 | $57.77 | -0.22% |
| Oct 31, 2024 | $50.57 | $57.15 | +13.01% |
| Aug 06, 2024 | $51.94 | $54.12 | +4.20% |
| May 07, 2024 | $41.21 | $42.01 | +1.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Halozyme Therapeutics (HALO) report earnings?
Halozyme Therapeutics (HALO) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Halozyme Therapeutics (HALO) earnings time?
Halozyme Therapeutics (HALO) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HALO EPS forecast?
HALO EPS forecast for the fiscal quarter 2025 (Q1) is 0.96.
---